1 reports of this reaction
8.3% of all MENTHOL, CAMPHOR reports
#3 most reported adverse reaction
APPLICATION SITE VESICLES is the #3 most commonly reported adverse reaction for MENTHOL, CAMPHOR, manufactured by Chattem, Inc.. There are 1 FDA adverse event reports linking MENTHOL, CAMPHOR to APPLICATION SITE VESICLES. This represents approximately 8.3% of all 12 adverse event reports for this drug.
Patients taking MENTHOL, CAMPHOR who experience application site vesicles should discuss this symptom with their healthcare provider to determine whether it may be related to their medication and what alternatives may be available.
APPLICATION SITE VESICLES is moderately reported among MENTHOL, CAMPHOR users, representing a notable but not dominant share of adverse events.
In addition to application site vesicles, the following adverse reactions have been reported for MENTHOL, CAMPHOR:
The following drugs have also been linked to application site vesicles in FDA adverse event reports:
APPLICATION SITE VESICLES has been reported as an adverse event in 1 FDA reports for MENTHOL, CAMPHOR. This does not prove causation, but indicates an association observed in post-market surveillance data.
APPLICATION SITE VESICLES accounts for approximately 8.3% of all adverse event reports for MENTHOL, CAMPHOR, making it one of the most commonly reported side effect.
If you experience application site vesicles while taking MENTHOL, CAMPHOR, contact your healthcare provider. They can evaluate whether the symptom is related to your medication and discuss potential adjustments to your treatment plan. Do not stop taking prescribed medication without consulting your doctor.